

Randomized Phase II Study of Triapine Radiochemotherapy

Charles Kunos, MD, PhD

Medical Officer, Investigational Drug Branch

Protocol NRG GY-006

Activated for Accrual: January 15, 2016

SCHEMA

Triapine (25 mg/m²)

Cisplatin (40 mg/m²)

Pelvic-field radiation
+ **brachytherapy**: 80 Gy

M → F

1



2

3

4

5

6





**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol